Role of Galectin-3 in Tumour Metastasis

被引：0

作者：

Radosavljevic G.D. ^{[1
]}

Jovanovic I.P. ^{[1
]}

Knezevic M.G. ^{[1
]}

Zdravkovic N.S. ^{[1
]}

Pavlovic S.M. ^{[1
]}

Lukic M.L. ^{[1
,2
]}

Arsenijevic N.N. ^{[1
]}

机构：

[1] Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Kragujevac

[2] Department of Microbiology/Immunology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain

来源：

Moscow University Chemistry Bulletin | 2010年 / 65卷 / 3期

关键词：

B16F1; Galectin-3; malignant melanoma; metastasis;

D O I：

10.3103/S0027131410030107

中图分类号：

学科分类号：

摘要：

We used metastatic variant of B16 melanoma (B16F1) to study lung colonization galectin-3-deficient (gal-3-/-) C57BL/6 mice. In vivo study showed that compared with gal-3+/+ mice, gal-3-/-mice exhibited resistance to lung colonization of B16F1 melanoma cells (p < 0.03). In vitro assays showed higher number of attached malignant cells in the tissue section derived from gal-3+/+ mice (p < 0.001) and tumor specific cytotoxicity of lymphoid cells of tumour inoculated gal-3-/- suggesting that galectin-3 is considered as therapeutic target. © 2010 Allerton Press, Inc.

引用

页码：159 / 164

页数：5

共 45 条

[1] Danguy A., Camby I., Kiss R., Biochim. Biophys. Acta, 1572, (2002)
[2] Liu F.T., Rabinovich G.A., Nat. Rev. Cancer., 5, (2005)
[3] Prieto V.G., Mourad-Zeidan A.A., Melnikova V., Et al., Clin. Cancer Res., 12, (2006)
[4] Krishnan V., Bane S.M., Kawle P.D., Et al., Clin. Exp. Metastasis, 22, (2005)
[5] Thijssen V.L., Poirier F., Baum L.G., Griffioen A.W., Blood, 110, (2007)
[6] Yang R.Y., Rabinovich G.A., Liu F.T., Expert Rev. Mol. Med., 10, (2008)
[7] Rabinovich G.A., Toscano M.A., Nature Reviews Immunology, 9, (2009)
[8] Chen H.Y., Liu F.T., Yang R.Y., Arch. Immunol. Then Exp., 53, (2005)
[9] Dumic J., Dabelic S., Flogel M., Biochim. Biophys. Acta, 1760, (2006)
[10] Sato S., Nieminen J., Clycoconj. J., 19, (2004)

← 1 2 3 4 5 →